-
YHLO Biotech Partners with NCRCID to Develop Advanced Tuberculosis Diagnostics
•
China-based Shenzhen YHLO Biotech Co., Ltd has entered into a strategic partnership with the National Clinical Research Center for Infectious Diseases (NCRCID) to develop advanced tuberculosis diagnosis products. The collaboration aims to enhance diagnostic capabilities for tuberculosis, a critical area of focus for both organizations. No financial details were disclosed…
-
Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
•
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused…
-
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
•
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova Medicines to advance a series of clinical studies. The collaboration will assess a combination regimen of Akeso’s AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), with LaNova’s LM-302,…
-
Lee’s Pharmaceutical Subsidiary Secures Distribution Deal for NVK002 in South Korea
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced a distribution and supply agreement with South Korea-based Kwangdong Pharmaceutical Co., Ltd (KRX: 009290) for NVK002, an atropine external use eye solution. Agreement Details and Financial TermsAccording to the agreement, Kwangdong will handle…
-
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu Biopharmaceutical Co., Ltd, has obtained clinical trial approvals for two in-house developed drugs: CD80 mutant Fc fusion protein XZP-KM602 and DNA dependent protein kinase (DNA-PK) inhibitor XZP-6877. Both drugs are aimed at treating advanced solid…
-
Shenzhen YHLO Biotech Partners with NCRCID for Advanced Tuberculosis Diagnostics
•
China-based Shenzhen YHLO Biotech Co., Ltd has announced a strategic partnership with the National Clinical Research Center for Infectious Diseases (NCRCID) to develop advanced tuberculosis diagnosis products. The collaboration aims to leverage both entities’ expertise to enhance diagnostics in the field of infectious diseases, with a focus on tuberculosis. Financial…
-
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
•
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a previous 2019 partnership between the two firms, which…
-
Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors
•
China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova Medicines to advance a series of clinical studies. These studies will assess the combination regimen of Akeso’s AK112, a bispecific antibody (BsAb) targeting programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF), alongside LaNova’s LM-302,…
-
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency Use Authorization (EUA) for its in-house developed COVID-19 mRNA vaccine, SYS6006, in China. This approval marks a significant milestone as it is the first for a domestically developed mRNA product in the country. SYS6006 Design…
-
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
•
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million) through a private placement of 355 million shares. The funds raised will be allocated towards several key projects, including the expansion of peritoneal dialysate production capacity, construction of a drug packaging material production base, development…
-
Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
•
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial People’s Hospital in the field of kidney disease. The collaboration aims to advance research and development in this critical area of healthcare. No financial details were disclosed in the partnership agreement. Everest’s Pipeline in Kidney…
-
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
•
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its XZP-KM501 (KM501) in solid tumors with HER2 positive, middle to low-expression. This marks a significant step forward in the development of innovative treatments for…
-
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
•
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from the Center for Drug Evaluation (CDE) for its potential first-in-class monoclonal antibody (mAb) FB1001 (ZG103). This marks a significant milestone in the development of the drug candidate, which was developed by the company’s founder, Dr.…
-
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
•
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its antibody-drug conjugate (ADC) candidate RC48 (disitamab vedotin). The Chinese firm is set to assess the drug as a neo-adjuvant therapy for HR-positive, HER2 low-expression breast cancer, either in combination with Junshi Bio’s (HKG: 1877, SHA:…
-
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
•
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of renminbi in a recent financing round, led solely by Cui Capital. The funds will be directed towards the clinical transformation of spatial proteomics tumor immune microenvironment assessment, the development of functional proteomics solutions, and the…
-
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
•
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186) lurbinectedin (LY01017), an RNA polymerase II inhibitor, is set to obtain priority review status for the treatment of metastatic small cell lung cancer (SCLC) with tumor progression during or after platinum-based chemotherapy. Development and Mechanism…
-
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional marketing approval from the National Medical Products Administration (NMPA) for its drug candidate RAY1216, a 3CL protease (3CLpro) inhibitor. The drug is set to be assessed as a treatment for mild to moderate COVID-19. Mechanism…
-
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its investigational drug HRS-5965. The study will focus on complement-mediated hemolytic anemia, including conditions such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic…
-
Sunshine Guojian Completes Patient Enrollment for SSGJ-611 Phase II Study in Atopic Dermatitis
•
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has announced the completion of patient enrollment in a China-based Phase II clinical study for its SSGJ-611, an IL-4Rα monoclonal antibody (mAb). The drug is being evaluated as a treatment for moderate to severe atopic dermatitis…
-
Henlius Biotech’s Serplulimab Accepted for EMA Review for ES-SCLC Treatment
•
Shanghai Henlius Biotech (HKG: 2696) has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for its programmed death-1 (PD-1) inhibitor, HanSiZhuang (serplulimab). The drug is filed for its first indication as a first-line treatment in combination with chemotherapy for extensive-stage small cell lung cancer…
